NASDAQ:LNSR LENSAR - LNSR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding LENSAR, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $2.33 -0.02 (-0.85%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$2.20▼$2.4750-Day Range$2.33▼$3.2752-Week Range$2.15▼$8.80Volume21,352 shsAverage Volume21,582 shsMarket Capitalization$25.86 millionP/E RatioN/ADividend YieldN/APrice Target$14.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media LENSAR MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside500.9% Upside$14.00 Price TargetShort InterestHealthy0.42% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.14Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.63 out of 5 starsMedical Sector844th out of 983 stocksSurgical & Medical Instruments Industry84th out of 100 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, LENSAR has a forecasted upside of 500.9% from its current price of $2.33.Amount of Analyst CoverageLENSAR has received no research coverage in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted0.42% of the float of LENSAR has been sold short.Short Interest Ratio / Days to CoverLENSAR has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LENSAR has recently decreased by 3.37%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLENSAR does not currently pay a dividend.Dividend GrowthLENSAR does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LNSR. Previous Next 1.7 News and Social Media Coverage News SentimentLENSAR has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for LENSAR this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, LENSAR insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of LENSAR is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions54.43% of the stock of LENSAR is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of LENSAR is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LENSAR is -1.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLENSAR has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About LENSAR (NASDAQ:LNSR) StockLENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.Read More Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Email Address LNSR Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comThe Consensus EPS Estimates For LENSAR, Inc. (NASDAQ:LNSR) Just Fell A LotMarch 20, 2023 | finance.yahoo.comLENSAR, Inc. (NASDAQ:LNSR) Q4 2022 Earnings Call TranscriptMarch 21, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 18, 2023 | seekingalpha.comLENSAR, Inc. (LNSR) Q4 2022 Earnings Call TranscriptMarch 18, 2023 | markets.businessinsider.comLENSAR (LNSR) Gets a Buy from BTIGMarch 16, 2023 | msn.comLENSAR GAAP EPS of -$0.24 beats by $0.01, revenue of $10.2M beats by $0.2MMarch 16, 2023 | finance.yahoo.comLENSAR Reports Fourth Quarter and Full Year 2022 Results and Provides Business UpdateMarch 15, 2023 | benzinga.comA Preview Of LENSAR's EarningsMarch 21, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 15, 2023 | americanbankingnews.comLENSAR (LNSR) Set to Announce Quarterly Earnings on ThursdayMarch 9, 2023 | finance.yahoo.comLENSAR to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023March 7, 2023 | finance.yahoo.comIs LENSAR (NASDAQ:LNSR) In A Good Position To Invest In Growth?February 16, 2023 | seekingalpha.comLensar reports Q4 revenue $10.2M, consensus $10MFebruary 16, 2023 | nasdaq.comSilver Point Capital Now Owns 4.40% of LENSAR (LNSR)February 14, 2023 | finance.yahoo.comLENSAR Announces Preliminary Fourth Quarter and Full Year 2022 ResultsDecember 13, 2022 | msn.comLENSAR Earnings Perspective: Return On Capital EmployedNovember 12, 2022 | seekingalpha.comLENSAR, Inc. (LNSR) Q3 2022 Earnings Call TranscriptNovember 9, 2022 | finance.yahoo.comLENSAR Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 2, 2022 | finance.yahoo.comLENSAR to Report Third Quarter 2022 Financial Results on Wednesday, November 9, 2022September 28, 2022 | ca.finance.yahoo.comWe're Hopeful That LENSAR (NASDAQ:LNSR) Will Use Its Cash WiselySeptember 9, 2022 | finanznachrichten.deLENSAR, Inc.: LENSAR Announces Application for Certification of the ALLY Adaptive Cataract Treatment System in the EUSeptember 8, 2022 | finance.yahoo.comLENSAR Announces Application for Certification of the ALLY™ Adaptive Cataract Treatment System in the EUSeptember 3, 2022 | nasdaq.comThe past year for LENSAR (NASDAQ:LNSR) investors has not been profitableAugust 16, 2022 | finance.yahoo.comFirst Patients Treated with LENSAR’s® ALLY™ Adaptive Cataract Treatment SystemAugust 1, 2022 | finance.yahoo.comLENSAR to Report Second Quarter 2022 Financial Results on Monday, August 8, 2022June 13, 2022 | finance.yahoo.comWhy Lensar Shares Are Trading Higher TodayJune 13, 2022 | seekingalpha.comLENSAR stock jumps premarket as FDA clears ALLY adaptive cataract treatment systemSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LNSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LENSAR and its competitors with MarketBeat's FREE daily newsletter. Email Address LNSR Company Calendar Last Earnings11/08/2021Today3/21/2023Next Earnings (Estimated)5/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LNSR CUSIPN/A CIK1320350 Webwww.lensar.com Phone888-536-7271FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+500.9%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)($1.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,910,000.00 Net Margins-56.32% Pretax Margin-56.32% Return on Equity-44.43% Return on Assets-34.69% Debt Debt-to-Equity RatioN/A Current Ratio2.95 Quick Ratio1.92 Sales & Book Value Annual Sales$35.36 million Price / Sales0.73 Cash FlowN/A Price / Cash FlowN/A Book Value$3.81 per share Price / Book0.61Miscellaneous Outstanding Shares11,100,000Free Float8,993,000Market Cap$25.86 million OptionableNot Optionable Beta-0.24 Key ExecutivesMr. Nicholas T. Curtis (Age 66)CEO & Director Comp: $888.59kMr. Thomas R. Staab II (Age 54)CPA, CFO & Sec. Comp: $556.51kMr. Alan B. Connaughton (Age 50)Chief Operating Officer Comp: $594.93kMs. Kendra W. Wong (Age 42)Principal Accounting Officer Key CompetitorsSTRATA Skin SciencesNASDAQ:SSKNBrainsWayNASDAQ:BWAYVapothermNYSE:VAPOGBSNYSE:GBSTenon MedicalNASDAQ:TNONView All CompetitorsInsiders & InstitutionsNorth Run Capital LPBought 161,896 shares on 2/15/2023Ownership: 9.949%Silver Point Capital L.P.Sold 357,169 shares on 2/15/2023Ownership: 4.363%Millennium Management LLCSold 33,258 shares on 2/15/2023Ownership: 0.643%Renaissance Technologies LLCSold 14,100 shares on 2/13/2023Ownership: 2.880%Simplex Trading LLCSold 900 shares on 2/2/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions LNSR Stock - Frequently Asked Questions What is LENSAR's stock price forecast for 2023? 0 Wall Street analysts have issued 12-month price objectives for LENSAR's shares. Their LNSR share price forecasts range from $14.00 to $14.00. On average, they expect the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 500.9% from the stock's current price. View analysts price targets for LNSR or view top-rated stocks among Wall Street analysts. How have LNSR shares performed in 2023? LENSAR's stock was trading at $2.96 at the beginning of the year. Since then, LNSR stock has decreased by 21.3% and is now trading at $2.33. View the best growth stocks for 2023 here. When is LENSAR's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023. View our LNSR earnings forecast. How were LENSAR's earnings last quarter? LENSAR, Inc. (NASDAQ:LNSR) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.06. The business had revenue of $8.27 million for the quarter, compared to analyst estimates of $7.67 million. LENSAR had a negative trailing twelve-month return on equity of 44.43% and a negative net margin of 56.32%. During the same quarter last year, the company posted ($0.64) earnings per share. What guidance has LENSAR issued on next quarter's earnings? LENSAR issued an update on its fourth quarter 2022 earnings guidance on Tuesday, February, 14th. The company provided EPS guidance of for the period. The company issued revenue guidance of $10.20 million-$10.20 million, compared to the consensus revenue estimate of $10.00 million. What is LENSAR's stock symbol? LENSAR trades on the NASDAQ under the ticker symbol "LNSR." Who are LENSAR's major shareholders? LENSAR's stock is owned by many different retail and institutional investors. Top institutional investors include North Run Capital LP (9.95%), Silver Point Capital L.P. (4.36%), Renaissance Technologies LLC (2.88%), Millennium Management LLC (0.64%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Gary M Winer and Thomas R Staab II. View institutional ownership trends. How do I buy shares of LENSAR? Shares of LNSR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is LENSAR's stock price today? One share of LNSR stock can currently be purchased for approximately $2.33. How much money does LENSAR make? LENSAR (NASDAQ:LNSR) has a market capitalization of $25.86 million and generates $35.36 million in revenue each year. The company earns $-19,910,000.00 in net income (profit) each year or ($1.97) on an earnings per share basis. How many employees does LENSAR have? The company employs 110 workers across the globe. How can I contact LENSAR? The official website for the company is www.lensar.com. The company can be reached via phone at 888-536-7271 or via email at ir.contact@lensar.com. This page (NASDAQ:LNSR) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.